| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Randy D Gascoyne | Q87831803 |
| P2093 | author name string | Christian Steidl | |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| P304 | page(s) | 2659-2669 | |
| P577 | publication date | 2011-06-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The molecular pathogenesis of primary mediastinal large B-cell lymphoma | |
| P478 | volume | 118 |
| Q34326409 | A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers |
| Q43135354 | A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy |
| Q38240579 | Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era. |
| Q44777053 | Assessing the effectiveness of a Grand Rounds CME activity for health-care professionals |
| Q83213559 | Cancer stem cells: an evolving concept |
| Q99583891 | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| Q38822525 | Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science |
| Q34612336 | Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma |
| Q48256921 | Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. |
| Q33747063 | Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features |
| Q33168244 | Composite Lymphoma: Opposite Ends of Spectrum Meet |
| Q26769596 | Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview |
| Q38754419 | Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. |
| Q38882112 | Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine |
| Q38161760 | Diffuse large B-cell lymphoma-treatment approaches in the molecular era. |
| Q33622342 | Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? |
| Q47681393 | Discovery and application of immune biomarkers for hematological malignancies. |
| Q48616433 | Evaluation of primary mediastinal large B cell lymphoma by flow cytometry |
| Q89184576 | Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence |
| Q34221760 | FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma. |
| Q36051184 | Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma |
| Q35974341 | Genetic lesions in diffuse large B-cell lymphomas |
| Q35882774 | Grey zone lymphomas: lymphomas with intermediate features |
| Q38523971 | IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types |
| Q41620612 | Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling |
| Q51804722 | Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. |
| Q58690185 | Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma |
| Q97643982 | Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives |
| Q38919386 | Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents |
| Q39154624 | Lentiviral vector-mediated siRNA knockdown of c-MYC: cell growth inhibition and cell cycle arrest at G2/M phase in Jijoye cells |
| Q57174502 | Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective |
| Q34636963 | MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples |
| Q38902828 | Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. |
| Q36474669 | Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q98770567 | Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a poten |
| Q36529482 | Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy |
| Q38996724 | PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas |
| Q34245261 | Pathogenesis of human B cell lymphomas |
| Q38245874 | Pathogenesis, diagnosis, and treatment of composite lymphomas |
| Q47567402 | Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. |
| Q34266819 | Primary mediastinal large B-cell lymphoma |
| Q37725413 | Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting |
| Q34455499 | Primary mediastinal lymphoma: diagnosis and treatment options |
| Q94521038 | Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up |
| Q31116522 | Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma |
| Q48371974 | R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis |
| Q38782141 | Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children |
| Q38764010 | Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma |
| Q35095028 | Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma |
| Q42368339 | Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay |
| Q37138531 | STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). |
| Q38150876 | Signaling pathways in lymphoma: pathogenesis and therapeutic targets |
| Q38267888 | Structural genomic alterations in primary mediastinal large B-cell lymphoma |
| Q36596879 | Targetable genetic features of primary testicular and primary central nervous system lymphomas |
| Q42950480 | Targeting STAT6 in PMBL. |
| Q42782702 | Targeting the intratumor heterogeneity in PMBL. |
| Q37988965 | The B7 homologues and their receptors in hematologic malignancies. |
| Q30396342 | The Microscope as a Tool for Disease Discovery-A Personal Voyage |
| Q26866537 | The genetic landscape of diffuse large B-cell lymphoma |
| Q38664822 | The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies |
| Q38203924 | The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. |
| Q38933091 | Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. |
| Q61053563 | Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma |
Search more.